{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:45:23Z","timestamp":1787003123140,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AI100853"],"award-info":[{"award-number":["T32AI100853"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI148574"],"award-info":[{"award-number":["AI148574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011643","name":"Blavatnik Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004851","name":"New York City Department of Health and Mental Hygiene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016027","name":"NYU Grossman School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01475-z","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:13:31Z","timestamp":1778174011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comparison of two- and three-dose MVA-BN mpox vaccination series on anti-monkeypox virus immunity"],"prefix":"10.1038","volume":"11","author":[{"given":"Aaron L.","family":"Oom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesi K.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie I.","family":"Samanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica C.","family":"Kottkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin Sedaghat","family":"Herati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the NYC OSMI Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Abdulai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Arciuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Carmody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamia","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Dontino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Edwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Engelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Geesey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Goins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Guevarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Haiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaliyah","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Jano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trishala","family":"Karmacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Knutsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Null","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Nweke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitha","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurchetan","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Suman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Talanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meron","family":"Tasissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Swindell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy P.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miilani","family":"Yonatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heekoung Allison","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"1475_CR1","unstructured":"Global Mpox Trends. Accessed 30 July 2025. https:\/\/worldhealthorg.shinyapps.io\/mpx_global\/."},{"key":"1475_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1126\/science.add4153","volume":"378","author":"CM Gigante","year":"2022","unstructured":"Gigante, C. M. et al. Multiple lineages of monkeypox virus detected in the United States, 2021\u20132022. Science 378, 560\u2013565 (2022).","journal-title":"Science"},{"key":"1475_CR3","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-022-01907-y","volume":"28","author":"J Isidro","year":"2022","unstructured":"Isidro, J. et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat. Med. 28, 1569\u20131572 (2022).","journal-title":"Nat. Med."},{"key":"1475_CR4","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1016\/j.vaccine.2020.01.058","volume":"38","author":"ET Overton","year":"2020","unstructured":"Overton, E. T. et al. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine 38, 2600\u20132607 (2020).","journal-title":"Vaccine"},{"key":"1475_CR5","doi-asserted-by":"crossref","unstructured":"Qin, L., Favis, N., Famulski, J. & Evans, D. H. Evolution of and evolutionary relationships between extant vaccinia virus strains. J. Virol. 89, 1809\u20131824 (2015).","DOI":"10.1128\/JVI.02797-14"},{"key":"1475_CR6","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.amjmed.2008.08.019","volume":"121","author":"DD Taub","year":"2008","unstructured":"Taub, D. D. et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am. J. Med. 121, 1058\u20131064 (2008).","journal-title":"Am. J. Med."},{"key":"1475_CR7","doi-asserted-by":"publisher","first-page":"e0169247","DOI":"10.1371\/journal.pone.0169247","volume":"12","author":"BM Slike","year":"2017","unstructured":"Slike, B. M., Creegan, M., Marovich, M. & Ngauy, V. Humoral immunity to primary smallpox vaccination: impact of childhood versus adult immunization on vaccinia vector vaccine development in military populations. PLoS ONE 12, e0169247 (2017).","journal-title":"PLoS ONE"},{"key":"1475_CR8","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1475_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/nm917","volume":"9","author":"E Hammarlund","year":"2003","unstructured":"Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9, 1131\u20131137 (2003).","journal-title":"Nat. Med."},{"key":"1475_CR10","doi-asserted-by":"publisher","unstructured":"Oom, A. L. et al. The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response. J. Virol. 99, https:\/\/doi.org\/10.1128\/jvi.00253-25 (2025).","DOI":"10.1128\/jvi.00253-25"},{"key":"1475_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","volume":"29","author":"LM Zaeck","year":"2023","unstructured":"Zaeck, L. M. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat. Med. 29, 270\u2013278 (2023).","journal-title":"Nat. Med."},{"key":"1475_CR12","doi-asserted-by":"publisher","unstructured":"Crandell, J. et al. The impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study. Lancet Microbe. 6, https:\/\/doi.org\/10.1016\/j.lanmic.2025.101098 (2025).","DOI":"10.1016\/j.lanmic.2025.101098"},{"key":"1475_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jama.2024.20951","volume":"332","author":"AY Collier","year":"2024","unstructured":"Collier, A. Y. et al. Decline of Mpox antibody responses after modified vaccinia Ankara\u2013Bavarian Nordic vaccination. JAMA 332, 1669\u20131672 (2024).","journal-title":"JAMA"},{"key":"1475_CR14","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","volume":"23","author":"H Cohn","year":"2023","unstructured":"Cohn, H. et al. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study. Lancet Infect. Dis. 23, 1302\u20131312 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1475_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3201\/eid3102.241300","volume":"31","author":"K Phipps","year":"2025","unstructured":"Phipps, K. et al. Short-lived neutralizing antibody responses to Monkeypox virus in Smallpox Vaccine\u2013Naive persons after JYNNEOS vaccination. Emerg. Infect. Dis. 31, 237\u2013245 (2025).","journal-title":"Emerg. Infect. Dis."},{"key":"1475_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/infdis\/jiae515","volume":"231","author":"CN Selverian","year":"2025","unstructured":"Selverian, C. N. et al. Monkeypox virus infection stimulates a more robust and durable neutralizing antibody response compared to modified vaccinia virus Ankara vaccination. J. Infect. Dis. 231, 1069\u20131073 (2025).","journal-title":"J. Infect. Dis."},{"key":"1475_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/vaccines13050520","volume":"13","author":"G Abate","year":"2025","unstructured":"Abate, G. et al. Differences in Mpox and vaccinia immunity induced by non-replicating and replicating vaccinia-based vaccines. Vaccines 13, 520 (2025).","journal-title":"Vaccines"},{"key":"1475_CR18","doi-asserted-by":"crossref","unstructured":"Van Dijck, C. et al. Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study. Lancet Infect. Dis. 26, 190-202 (2026).","DOI":"10.1016\/S1473-3099(25)00545-6"},{"key":"1475_CR19","doi-asserted-by":"publisher","first-page":"100024","DOI":"10.1016\/j.lanprc.2025.100024","volume":"1","author":"EE Evans","year":"2025","unstructured":"Evans, E. E. & Titanji, B. K. Protection that lasts? MVA-BN against clade IIb mpox. Lancet Prim. Care 1, 100024 (2025).","journal-title":"Lancet Prim. Care"},{"key":"1475_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1473-3099(25)00082-9","volume":"25","author":"AR Raccagni","year":"2025","unstructured":"Raccagni, A. R. & Nozza, S. Mpox vaccination: a dose of protection, but is it enough. Lancet Infect. Dis. 25, 709\u2013710 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1475_CR21","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.lanprc.2025.100018","volume":"1","author":"NH Latham","year":"2025","unstructured":"Latham, N. H. et al. Clinical features of mpox in fully vaccinated people in New South Wales, Australia: an outbreak investigation and retrospective cohort study. Lancet Prim. Care 1, 100018 (2025).","journal-title":"Lancet Prim. Care"},{"key":"1475_CR22","doi-asserted-by":"publisher","first-page":"460","DOI":"10.15585\/mmwr.mm7320a3","volume":"73","author":"SAJ Guagliardo","year":"2024","unstructured":"Guagliardo, S. A. J. et al. Monkeypox virus infections after 2 preexposure doses of JYNNEOS vaccine\u2014United States, May 2022\u2013May 2024. MMWR Morb. Mortal. Wkly Rep. 73, 460\u2013466 (2024).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1475_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1473-3099(23)00492-9","volume":"24","author":"A Hazra","year":"2024","unstructured":"Hazra, A. et al. Mpox in people with past infection or a complete vaccination course: a global case series. Lancet Infect. Dis. 24, 57\u201364 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1475_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7225a6","volume":"72","author":"EAG Faherty","year":"2025","unstructured":"Faherty, E. A. G. et al. Notes from the field: emergence of an Mpox cluster primarily affecting persons previously vaccinated against Mpox \u2014 Chicago, Illinois, March 18\u2013June 12, 2023. Morb. Mortal. Wkly Rep. 72, 696\u2013698 (2025).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"1475_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/infdis\/jiac455","volume":"227","author":"H Ilchmann","year":"2023","unstructured":"Ilchmann, H. et al. One- and two-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic induce durable B-cell memory responses comparable to replicating smallpox vaccines. J. Infect. Dis. 227, 1203\u20131213 (2023).","journal-title":"J. Infect. Dis."},{"key":"1475_CR26","doi-asserted-by":"publisher","unstructured":"Priyamvada, L. et al. MVA-BN third-dose 5 years after primary; Democratic Republic of the Congo. https:\/\/doi.org\/10.1016\/S1473-3099(26)00001-0 (2025).","DOI":"10.1016\/S1473-3099(26)00001-0"},{"key":"1475_CR27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.chom.2023.05.001","volume":"31","author":"M Hubert","year":"2023","unstructured":"Hubert, M. et al. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. Cell Host Microbe 31, 937\u2013948.e4 (2023).","journal-title":"Cell Host Microbe"},{"key":"1475_CR28","doi-asserted-by":"publisher","unstructured":"Mari\u00ebn, J. et al. Diagnostic accuracy of a high-throughput multiplex immunoassay for the detection of Mpox virus infection and MVA-BN vaccination up to two years after exposure. Preprint at https:\/\/doi.org\/10.1101\/2025.06.12.25329495 (2025).","DOI":"10.1101\/2025.06.12.25329495"},{"key":"1475_CR29","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1073\/pnas.1520112113","volume":"113","author":"C Havenar-Daughton","year":"2016","unstructured":"Havenar-Daughton, C. et al. CXCL13 is a plasma biomarker of germinal center activity. Proc. Natl. Acad. Sci. USA 113, 2702\u20132707 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1475_CR30","doi-asserted-by":"publisher","unstructured":"Eisenbarth, S. C. et al. A roadmap for defining \u201cextrafollicular\u201d B cell responses. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2025.08.007 (2025).","DOI":"10.1016\/j.immuni.2025.08.007"},{"key":"1475_CR31","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1126\/scitranslmed.abi8961","volume":"14","author":"MI Samanovic","year":"2022","unstructured":"Samanovic, M. I. et al. Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2\u2013experienced individuals. Sci. Transl. Med. 14, 8961 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1475_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","volume":"604","author":"W Kim","year":"2022","unstructured":"Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141\u2013145 (2022).","journal-title":"Nature"},{"key":"1475_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2021.12.004","volume":"30","author":"A Tauzin","year":"2022","unstructured":"Tauzin, A. et al. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host Microbe 30, 97\u2013109.e5 (2022).","journal-title":"Cell Host Microbe"},{"key":"1475_CR34","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","volume":"184","author":"RP Payne","year":"2021","unstructured":"Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699\u20135714.e11 (2021).","journal-title":"Cell"},{"key":"1475_CR35","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1093\/cid\/ciac290","volume":"75","author":"DM Skowronski","year":"2022","unstructured":"Skowronski, D. M. et al. Two-dose severe acute respiratory syndrome Coronavirus 2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Clin. Infect. Dis. 75, 1980\u20131992 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1475_CR36","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1056\/NEJMc2306239","volume":"389","author":"AC Kottkamp","year":"2023","unstructured":"Kottkamp, A. C. et al. Antibody titers against Mpox virus after vaccination. N. Engl. J. Med. 389, 2299\u20132301 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1475_CR37","unstructured":"U.S. Case Trends: Clade II Mpox | Mpox | CDC. Accessed 25 September 2025. https:\/\/www.cdc.gov\/mpox\/data-research\/cases\/index.html."},{"key":"1475_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59370-5","volume":"16","author":"JL Chen","year":"2025","unstructured":"Chen, J. L. et al. T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination. Nat. Commun. 16, 4362 (2025).","journal-title":"Nat. Commun."},{"key":"1475_CR39","doi-asserted-by":"publisher","unstructured":"Ju, B. et al. Structurally conserved human anti-A35 antibodies protect mice and macaques from mpox virus infection. Cell https:\/\/doi.org\/10.1016\/j.cell.2025.08.005 (2025).","DOI":"10.1016\/j.cell.2025.08.005"},{"key":"1475_CR40","doi-asserted-by":"publisher","unstructured":"Fantin, R. F. et al. Human monoclonal antibodies targeting A35 protect from death caused by mpox. Cell https:\/\/doi.org\/10.1016\/j.cell.2025.08.004 (2025).","DOI":"10.1016\/j.cell.2025.08.004"},{"key":"1475_CR41","doi-asserted-by":"publisher","unstructured":"Meola, A. et al. Structural basis of poxvirus fusion regulation and anti-A16\/G9 antibody-mediated neutralization and protection. Cell https:\/\/doi.org\/10.1016\/j.cell.2025.07.040 (2025).","DOI":"10.1016\/j.cell.2025.07.040"},{"key":"1475_CR42","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.chom.2023.04.015","volume":"31","author":"S Adamo","year":"2023","unstructured":"Adamo, S. et al. Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. Cell Host Microbe 31, 928\u2013936.e4 (2023).","journal-title":"Cell Host Microbe"},{"key":"1475_CR43","doi-asserted-by":"publisher","first-page":"105957","DOI":"10.1016\/j.isci.2023.105957","volume":"26","author":"R Yefet","year":"2023","unstructured":"Yefet, R. et al. Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens. iScience 26, 105957 (2023).","journal-title":"iScience"},{"key":"1475_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3851\/IMP1573","volume":"15","author":"MM McCausland","year":"2010","unstructured":"McCausland, M. M. et al. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir. Ther. 15, 661\u2013675 (2010).","journal-title":"Antivir. Ther."},{"key":"1475_CR45","doi-asserted-by":"publisher","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","volume":"79","author":"DH Davies","year":"2005","unstructured":"Davies, D. H. et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79, 11724\u201311733 (2005).","journal-title":"J. Virol."},{"key":"1475_CR46","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1128\/JVI.00852-08","volume":"82","author":"H Bisht","year":"2008","unstructured":"Bisht, H., Weisberg, A. S. & Moss, B. Vaccinia virus L1 protein is required for cell entry and membrane fusion. J. Virol. 82, 8687\u20138694 (2008).","journal-title":"J. Virol."},{"key":"1475_CR47","doi-asserted-by":"crossref","unstructured":"Kaever, T. et al. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. J. Virol. 88, 11339\u201311355 (2014).","DOI":"10.1128\/JVI.01491-14"},{"key":"1475_CR48","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","volume":"167","author":"I Gilchuk","year":"2016","unstructured":"Gilchuk, I. et al. Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell 167, 684\u2013694.e9 (2016).","journal-title":"Cell"},{"key":"1475_CR49","doi-asserted-by":"publisher","first-page":"e1007826","DOI":"10.1371\/journal.ppat.1007826","volume":"15","author":"HW Chang","year":"2019","unstructured":"Chang, H. W. et al. Vaccinia viral A26 protein is a fusion suppressor of mature virus and triggers membrane fusion through conformational change at low pH. PLoS Pathog. 15, e1007826 (2019).","journal-title":"PLoS Pathog."},{"key":"1475_CR50","doi-asserted-by":"crossref","unstructured":"Kaever, T. et al. Linear epitopes in vaccinia virus A27 are targets of protective antibodies induced by vaccination against smallpox. J. Virol. 90, 4334\u20134345 (2016).","DOI":"10.1128\/JVI.02878-15"},{"key":"1475_CR51","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.virol.2008.08.009","volume":"380","author":"GE Nelson","year":"2008","unstructured":"Nelson, G. E., Sisler, J. R., Chandran, D. & Moss, B. Vaccinia virus entry\/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology 380, 394\u2013401 (2008).","journal-title":"Virology"},{"key":"1475_CR52","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1099\/vir.0.030460-0","volume":"92","author":"BC DeHaven","year":"2011","unstructured":"DeHaven, B. C., Gupta, K. & Isaacs, S. N. The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins. J. Gen. Virol. 92, 1971\u20131980 (2011).","journal-title":"J. Gen. Virol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01475-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01475-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01475-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:45:42Z","timestamp":1783986342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01475-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1475"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01475-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.M. reported potential competing interests: laboratory research and clinical trials contracts for vaccines or MAB with Lilly, Pfizer, and Sanofi; research grant funding from USG\/HHS\/NIH for vaccine and MAB clinical trials; personal fees for Scientific Advisory Board service from Hillevax, Merck, Meissa Vaccines, Sanofi, Pfizer, and GSK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}